hronic thromboembolic pulmonary hypertension (CTEPH) due to unresolved pulmonary embolism is a potentially correctable pulmonary hypertension (PH) by pulmonary thromboendarterectomy. [1] [2] [3] The incidence of this disease has been estimated as 0.1-0.5% in patients surviving acute pulmonary embolism. 1,2 However, it was recently reported that the incidence of this disease is in fact relatively high (3.8% at 2 years after acute pulmonary embolism). 4 In addition, a recent study based on mailed questionnaires in Japan revealed 169 new cases of acute pulmonary embolism and 17 new cases of CTEPH within 2 months, suggesting that the ratio of CTEPH to acute pulmonary thromboembolism (10.1%) might be high in Japan. 5 Without surgery the prognosis of CTEPH is thought to be poor, and the survival rate at 5 years is 30% in patients with mean pulmonary arterial pressure (Ppa) higher than 40 mmHg. 6 The precise mechanism of the progression of PH remains undefined. Although the extent of vascular obstruction is a major determinant, hemodynamic progression may involve recurrent thromboembolism or in situ thrombosis as well as pulmonary vascular remodeling. 2 The renin-angiotensin system plays a fundamental role in the onset and/or progression of a variety of cardiovascular diseases, 7-12 including venous thromboembolism. 13, 14 Angiotensin-converting enzyme (ACE) plays an important role in systemic vascular remodeling and also endothelial dysfunction. 12, 15, 16 As well as its involvement in the development of cardiovascular diseases, the ACE gene has also been considered a candidate for contributing to the development of exercise-induced PH in chronic obstructive pulmonary disease (COPD) patients in Japan. 17 The ACE gene contains a polymorphism based on the presence (insertion, I) or absence (deletion, D) within intron 16 of a 287-basepair nonsense DNA domain, resulting in 3 genotypes (II, DI, DD). 18 The D allele is associated with increased circulating and cellular concentrations of ACE, which could be related to increased cardiovascular risk including venous thromboembolism. 7, 12, 13, 19 In addition, increased expression of ACE has been reported in primary and secondary plexiform PH, 20 and ACE inhibition therapy delays pulmonary vascular neointimal formation. 21 The ACE genotype may contribute to vascular remodeling in distal pulmonary arteries even in CTEPH.
hronic thromboembolic pulmonary hypertension (CTEPH) due to unresolved pulmonary embolism is a potentially correctable pulmonary hypertension (PH) by pulmonary thromboendarterectomy. [1] [2] [3] The incidence of this disease has been estimated as 0.1-0.5% in patients surviving acute pulmonary embolism. 1, 2 However, it was recently reported that the incidence of this disease is in fact relatively high (3.8% at 2 years after acute pulmonary embolism). 4 In addition, a recent study based on mailed questionnaires in Japan revealed 169 new cases of acute pulmonary embolism and 17 new cases of CTEPH within 2 months, suggesting that the ratio of CTEPH to acute pulmonary thromboembolism (10.1%) might be high in Japan. 5 Without surgery the prognosis of CTEPH is thought to be poor, and the survival rate at 5 years is 30% in patients with mean pulmonary arterial pressure (Ppa) higher than 40 mmHg. 6 The precise mechanism of the progression of PH remains undefined. Although the extent of vascular obstruction is a major determinant, hemodynamic progression may involve recurrent thromboembolism or in situ thrombosis as well as pulmonary vascular remodeling. 2 The renin-angiotensin system plays a fundamental role in the onset and/or progression of a variety of cardiovascular diseases, [7] [8] [9] [10] [11] [12] including venous thromboembolism. 13, 14 Angiotensin-converting enzyme (ACE) plays an important role in systemic vascular remodeling and also endothelial dysfunction. 12, 15, 16 As well as its involvement in the development of cardiovascular diseases, the ACE gene has also been considered a candidate for contributing to the development of exercise-induced PH in chronic obstructive pulmonary disease (COPD) patients in Japan. 17 The ACE gene contains a polymorphism based on the presence (insertion, I) or absence (deletion, D) within intron 16 of a 287-basepair nonsense DNA domain, resulting in 3 genotypes (II, DI, DD). 18 The D allele is associated with increased circulating and cellular concentrations of ACE, which could be related to increased cardiovascular risk including venous thromboembolism. 7, 12, 13, 19 In addition, increased expression of ACE has been reported in primary and secondary plexiform PH, 20 and ACE inhibition therapy delays pulmonary vascular neointimal formation. 21 The ACE genotype may contribute to vascular remodeling in distal pulmonary arteries even in CTEPH.
We hypothesized that ACE-I/D polymorphism might be related to CTEPH susceptibility, severity of the disease, and its outcome.
CTEPH recruited from the respiratory inpatient departments of Chiba University Hospital between 1992 and 2004. CTEPH was defined as mean Ppa ≥25 mmHg with normal wedge pressure in patients who had dyspnea on exertion for a duration of more than 6 months. 3, 22, 23 In addition, lung perfusion scans demonstrated segmental or larger defects concomitant with the normal ventilation scan. Finally, the chronic thromboembolic findings were confirmed by pulmonary angiography. 24 Baseline characteristics are shown in Table 1 : 46 patients underwent pulmonary thromboendarterectomy (surgical group), and 49 patients were excluded from surgery because of a mild symptomatic degree of New York Heart Association functional class (NYHA) ≤2 (n=21), peripheral type of emboli (n=25), age >70 years (n=2), or a severe degree of PH (n=1) (medically treated group).
Baseline characteristics of the medically treated group are shown in Table 2 . In this group all but 1 patient, who was bleeding from hemangioma, were treated with warfarin. Diuretics were also used in 59.2% of the patients; those with NYHA ≥3 were treated with beraprost sodium (24 of 28 patients with NYHA 3 or 4 without side-effects or COPD, and 4 other patients with NYHA 2, were treated with beraprost sodium). An inferior vena cava filter was inserted in 27 of the patients. The control group consisted of 97 healthy volunteers, including staff of Chiba University and subjects attending for medical check-ups (56 males, 41 females, age 50.3±16.3 years), and all were Japanese living in eastern Japan, as was the patient group.
Study Design
Genotype and allele frequencies were compared between patients and controls. Clinical characteristics including pulmonary hemodynamics were compared among ACE genotypes (II, ID, DD) and between 2 groups (D allele carrier (ID plus DD) and non-carrier (II). Survival curves between ACE D allele carrier and non-carrier were compared in the medically treated group. Multivariate Cox proportional hazard regression analysis was used to determine whether ACE polymorphism had independent prognostic significance. The study protocol was approved by the Research Ethics Committees of the Graduate School of Medicine, Chiba University, and written informed consent was given by each subject.
Measurements
At least 3 months after an acute episode, pulmonary hemodynamics, cardiac output (by thermodilution technique), and blood gases were measured while the patient was supine and breathing room air. The cardiac index was calculated as cardiac output divided by body surface area. Pulmonary vascular resistance was calculated conventionally as the ratio of the difference between mean Ppa and pulmonary wedge pressure to cardiac output. Since 1998 the 6-min walk test while breathing room air or appropriate oxygen was performed within 1 week of catheterization in 63 of 95 patients.
Identification of I/D Polymorphism in ACE Gene
Genomic DNA was obtained from peripheral blood leukocytes using a QIAamp DNA blood minikit (Qiagen, Valencia, CA, USA). I/D polymorphism was examined by polymerase chain reaction (PCR) using the primers and methods described by Rigat et al. 18 Under certain condi- tions, the ACE D allele amplifies more effectively than the longer I allele, resulting in mistyping of ID as the DD genotype, 25 so all DD genotypes were reconfirmed. Briefly, the sense primer used in PCR was replaced with an I-specific primer that leads to selective amplification of the I allele and absence of the D allele in the mistyped ID genotype. No mistyping was identified.
Long-Term Outcome in the Medically Treated Group
Survival of the 49 medically treated patients was estimated from the date of initial diagnosis by right heart catheterization to March 1, 2005, or death. One patient who died of noncardiac cause (myeloma) was judged up to that point.
Survival and cause of death in the 46 surgical patients were also investigated up to March 1, 2005 .
Statistical Analysis
All data were expressed as mean ± SD. Genotype frequencies were compared between patients and controls by chi-square test. The Hardy-Weinberg equilibrium for genotype distribution was estimated by chi-square test.
Comparison of parameters between 2 groups (D allele carrier and non-carrier) was performed by unpaired t-test or chi-square test. Comparisons of parameters based on the 3 ACE genotypes were performed by 1-way analysis of variance, followed by Scheffe's multiple comparison test, or chi-square test. Survival curves between the 2 groups were obtained using the Kaplan-Meier method and compared by log-rank test. To determine whether ACE polymorphism has independent prognostic significance, age, mean Ppa, pulmonary vascular resistance, PaO2, and the presence or absence of beraprost sodium therapy were entered into multivariate Cox proportional hazards analysis. Backward, step-wise rejection of variables was employed at the 0.05 significance level. A p-value of less than 0.05 was considered significant.
Results
The frequencies of the genotypes and alleles of ACE-I/D polymorphism were not significantly different between patients and controls ( Table 3 ). The observed genotype frequencies were in agreement with the frequencies predicted by the Hardy-Weinberg equilibrium for each group. The baseline characteristics according to ACE genotype are shown in Table 4 . There were no significant differences in clinical characteristics among the 3 genotype groups, but ACE D allele carriers (ID plus DD) had a significantly lower 6-min walk test distance compared to ACE D allele non-carriers (II) (330±102 vs 381±85 m, p=0.046). When the baseline characteristics between ACE D allele carriers and non-carriers were compared in the medically treated group, ACE D allele carriers had significantly lower PaO2 and 6-min walk test distance than ACE D allele non-car- Tables 1-3. riers, and beraprost sodium was more frequently used in the ACE D allele carriers (Table 5) .
Survival Analysis
In the medically treated group, 10 patients died of cardiopulmonary causes (9 of right cardiac failure, 1 of hemoptysis) during a mean follow-up period of 4.4±2.9 (median 3.6) years. Four of them had the ACE DD genotype, 5 were ID genotype, and only 1 was II genotype. Among the survivors, 4 patients (DD 2, ID 1, II 1) were treated with intravenous prostacyclin or sildenafil because of progressive disease resistant to beraprost sodium treatment. KaplanMeier analysis of the medical treatment group revealed significantly deteriorated survival for D allele carriers compared with non-carriers (p=0.0389, log-rank test) (Fig 1) . The influence of D allele carrier on survival was significant when age, mean Ppa, PaO2, pulmonary vascular resistance, and the presence or absence of beraprost sodium therapy were entered into the multivariate Cox proportional hazards analysis. In this model, age (p=0.013), pulmonary vascular resistance (p=0.008), and D allele carrier (p=0.021) were independent predictors of survival (Table 6 ).
In the surgical group, 3 patients (DD 1, DI 1, II 1) died of right cardiac failure during the early postoperative period and 3 other patients died during the follow-up period: 1 with II genotype of right cardiac failure 10.6 years after surgery, and 2 (DI and II) of other causes.
Discussion
CTEPH has become a curative disease because pulmonary thromboendarterectomy is very effective for the central type of thrombi. [1] [2] [3] However, sometimes patients can not undergo surgery because they have the peripheral type of emboli, are older or have a severe grade of PH. The prognosis of CTEPH in medically treated patients is thought to be poor, 6 but Ono et al reported that beraprost sodium improves their survival. 26 Vascular remodeling could be an important factor for developing PH, even in CTEPH, as well as pulmonary arterial hypertension, and beraprost sodium might improve vascular remodeling. ACE plays an important role in systemic vascular remodeling and also in endothelial dysfunction. In addition, increased endothelial expression of ACE in small intraacinar pulmonary arteries has been shown in primary and secondary PH, and ACE inhibition therapy delays pulmonary vascular neointimal formation, suggesting that ACE contributes to pulmonary vascular remodeling. 12, 15, 16 The ACE gene has been proposed as a contributor to the development of exercise-induced PH in COPD patients in Japan, 17 so we hypothesized that ACE might also be related to CTEPH susceptibility, severity, and outcome.
In the present study we found that carrying the ACE D allele is a poor prognostic factor for medically treated CTEPH patients, independent of age and pulmonary vascular resistance. However, several issues need to be considered in the interpretation of these results.
In terms of patient survival analysis, the present patients consisted of only medically treated ones, and they predominantly had peripheral emboli. Thus, ACE D allele carrier status might be related to having only the peripheral type of CTEPH. Ethical reasons prevented us from observing the natural history of the central type of CTEPH patients receiving medical treatment, because it is clear that such patients can benefit from pulmonary endarterectomy.
The relationship between ACE genotype and survival remains obscure. Controversy has surrounded the role of ACE polymorphism. In the USA Abraham et al showed that the frequency of the ACE DD genotype was significantly higher in primary PH and that the DD genotype was associated with preserved right ventricular function. 27 In contrast, van Suyledn et al in The Netherlands showed that the DD genotype is negatively associated with right ventricular hypertrophy in COPD, indicating that patients with the DD genotype had mild PH or less adaptive right ventricular hypertrophy. 28 It was reported that pulmonary vascular resistance evoked by exercise was higher in patients with the DD genotype than with DI or II in Japanese COPD patients. 17 In our series, ACE D allele carriers had a lower 6-min walk distance. Our data support the notion that the ACE D allele or DD genotype is associated with less adaptive right ventricular hypertrophy or a higher degree of exercise-induced PH. The difference between primary and secondary PH and racial differences might be involved in these apparent discrepancies.
In addition, we measured the ratio of the right ventricle to left ventricle short-axis diameters (RV/LV) by multidetector computed tomography (CT) (data not shown). We could not find any significant difference in RV/LV (p>0.67, n=29) between D allele carriers and non-carriers. The assessment of right ventricular hypertrophy using ECGgated multidetector CT or magnetic resonance imaging might be helpful to further reveal the association of ACE polymorphism with right ventricular remodeling.
The ACE I/D polymorphism is associated with a 25% increase (DD) or decrease (II) in plasma activity relative Table 3 . to ID, 19 and D allele carrier status or DD genotype predisposes to various cardiovascular and renal diseases that tend to be progressive. [7] [8] [9] [10] [11] [12] 29, 30 As ACE activity increases on computer simulation, the plasma angiotensin II level scarcely changes but the level of bradykinin decreases substantially. 12, 31 It is suggested that a lower bradykinin level contributes to the disease progression in D allele carriers with diabetic nephropathy. 12 In addition to systemic ACE activity, local ACE activity in pulmonary arteries might be related to the poor prognosis of D allele carriers in our study.
It is well known that lower exercise tolerance is related to poor prognosis in severe PH. 32 We could not submit the 6-min walk test data to multivariate survival analysis, because disease severity meant that we performed this test for only about half of the nonsurvivors in the medical treatment group. ACE D allele carrier status might be related to some survival factor that is dependent on exercise tolerance.
In addition, ACE D allele carriers in the medically treated group had lower PaO2. However, multivariate analysis including age, mean Ppa, PaO2, pulmonary vascular resistance, and the presence or absence of beraprost sodium therapy showed that only age, pulmonary vascular resistance, and ACE D allele carrier status were independent prognostic factors.
We could not find any significant difference in the frequencies of the genotypes and alleles of ACE-I/D between patients and controls. It was reported that the frequency of the ACE DD genotype was lower in the Suita Study from the western part of Japan than that in the Framingham Heart Study from the USA. 29, 30 The Suita Study, which included the largest number of Japanese subjects (n=3,814), showed that the frequencies of the ACE DD, DI, II genotypes in controls were 12.3%, 44.8%, 42.9%, respectively. 29 Although the frequency of the DD genotype in CTEPH (18.9%) in our study was higher than that in the controls (12.3%) from the Suita Study with marginal significance (p=0.05, odds ratio 1.67), 2 other studies showed a slightly higher frequency of the DD genotype in controls: 18.7% (325 of 1,730) from the western part of Japan (Shigaraki Study), 33 and 13.6% (119 of 877) from the northeastern part of Japan (Shibata Study). 34 The present patients and controls were from the eastern part of Japan. Larger studies are needed to clarify whether the ACE DD genotype is related to susceptibility to CTEPH in Japanese.
Although bone morphogenetic protein receptor type II gene mutations have been seen in patients with primary PH, 35,36 they have not been identified in CTEPH, and we recently reported that HLA-B*5201 and HLA-DPB1*0202 were associated with CTEPH in Japan. 37 However, we could not find any relationship between these specific HLA alleles and ACE genotypes or alleles.
Ono et al reported that beraprost sodium improved survival, 26 but in our series multivariate analysis did not show any beneficial effect of beraprost on survival, partly because we used beraprost in only NYHA ≥3 or in patients with worsening symptoms. In severe disease, beraprost sodium treatment was not sufficiently effective for improving the survival of CTEPH.
Recently, we attempted to perform surgery for predominantly peripheral type CTEPH patients in whom the thrombi were located in only segmental arteries, classified as type 3 by Thistlethwaite et al. 38 Although our study is based on results from a single institution, the difference in prognosis based on ACE genotypes in the medically treated cases might lead to the recommendation of early surgery or extended surgical indication in CTEPH patients carrying the ACE D allele.
In conclusion, to our knowledge, this is the first report to show that ACE D allele carrier status might be one of the prognostic factors for medically treated CTEPH patients.
